Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Quality in Sport

Use of GLP-1 receptor agonists and dual agonists in patients with inflammatory bowel disease
  • Home
  • /
  • Use of GLP-1 receptor agonists and dual agonists in patients with inflammatory bowel disease
  1. Home /
  2. Archives /
  3. Vol. 77 (2026) /
  4. Medical Sciences

Use of GLP-1 receptor agonists and dual agonists in patients with inflammatory bowel disease

Authors

  • Michał Antoni Dróżdż Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland https://orcid.org/0009-0004-8933-0299
  • Maria Marcak Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland https://orcid.org/0009-0005-2810-798X
  • Weronika Nowicka Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland https://orcid.org/0009-0002-4555-3189
  • Anna Kożuch Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland https://orcid.org/0009-0000-6315-6895
  • Emilia Rymarczyk Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland https://orcid.org/0009-0009-2172-6429

DOI:

https://doi.org/10.12775/QS.2026.77.76265

Keywords

Inflammatory Bowel Disease, GLP-1 Receptor Agonists, Obesity, Tirzepatide, Mucosal Healing

Abstract

Background: Obesity represents a growing epidemiological problem in patients with inflammatory bowel disease (IBD), affecting up to 40% of patients. Excess adipose tissue worsens clinical prognosis, sustains systemic inflammation, and accelerates the loss of response to biological therapy.

Aim: The aim of this study was to summarize current knowledge regarding the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists (tirzepatide) in this patient group.

Materials and methods: PubMed Scopus, Web of Science, and Cochrane Library databases were searched from their inception through September 2026 using a combination of relevant keywords. A total of 20 studies were included in the review.

Results: Incretin-based therapies demonstrate immunomodulatory and intestinal barrier–protective effects. Real-world studies and meta-analyses show that semaglutide, liraglutide, and tirzepatide induce significant weight loss (6–12%+), reduce C-reactive protein levels, hospitalization rates, corticosteroid use, and the risk of IBD-related surgery by up to 55%. These agents are generally well tolerated and are not associated with an increased risk of IBD exacerbations. Delayed gastric emptying remains an important consideration, particularly in patients receiving oral thiopurines due to the potential for altered drug pharmacokinetics and hepatotoxicity.

Conclusions: GLP-1 and GIP/GLP-1 agonists represent a highly promising, safe adjunctive therapy for patients with IBD and metabolic disorders. Results from ongoing randomized controlled trials will allow for the definitive establishment of their position in gastroenterological guidelines.

References

1. Yang, M., Huo, Y., Liu, Z., Bai, G., He, D., & Zhang, L. (2025). The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis. Frontiers in medicine, 12, 1621958. https://doi.org/10.3389/fmed.2025.1621958

2. Ramos Belinchón, C., Martínez-Lozano, H., Serrano Moreno, C., Hernández Castillo, D., Lois Chicharro, P., Ferreira Ocampo, P., Marín-Jiménez, I., Bretón Lesmes, I., & Menchén, L. (2024). Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease. Revista espanola de enfermedades digestivas, 116(9), 478–483. https://doi.org/10.17235/reed.2024.10305/2024

3. Fernando, S., Zhao, J., Josloff, K., Zubair, N., Desai, A., Shivashankar, R., Kozuch, P. L., Choudhary, C., Lichtenstein, G., & Sehgal, P. (2026). Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms. Frontiers in gastroenterology (Lausanne, Switzerland), 5, 1864456. https://doi.org/10.3389/fgstr.2026.1864456

4. Maracle, B., Quan, S., Hamilton, P., Shaikh, A., Hazra, D., Lorenzetti, D. L., Gold, S. L., Raman, M., & St-Pierre, J. (2026). Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease. Alimentary pharmacology & therapeutics, 63(1), 17–39. https://doi.org/10.1111/apt.70485

5. Clarke, L., Passam, R. T., Falahee, B., Jirapinyo, P., Allegretti, J. R., & Kelly, C. R. (2025). Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease. Digestive diseases and sciences, 70(7), 2426–2432. https://doi.org/10.1007/s10620-025-08964-6

6. Weng, J., Alizadeh, M., & Friedman, S. (2025). Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease. Digestive diseases and sciences, 70(10), 3476–3484. https://doi.org/10.1007/s10620-025-09344-w

7. Desai, A., Khataniar, H., Tabaku, F., Hashash, J. G., Farraye, F. A., & Kochhar, G. S. (2026). Efficacy of tirzepatide for weight loss and it's comparative effectiveness to weight loss surgery in inflammatory bowel disease. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 45(3), 564–575. https://doi.org/10.1007/s12664-025-01835-y

8. Colwill, M., Povlsen, S., Pollok, R., Patel, K., Goodhand, J., Ahmad, T., & Honap, S. (2025). Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential. Journal of Crohn's & colitis, 19(9), jjaf167. https://doi.org/10.1093/ecco-jcc/jjaf167

9. Levine, J., Lee, Y. A., Pham, A., Guo, J., Dai, H., Radwan, R. M., Bian, J., Novikov, A., & Sheer, A. (2025). Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity. medRxiv : the preprint server for health sciences, 2025.11.13.25340005. https://doi.org/10.1101/2025.11.13.25340005

10. Anderson, S. R., Ayoub, M., Coats, S., McHenry, S., Tan, T., & Deepak, P. (2025). Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease. The American journal of gastroenterology, 120(5), 1152–1155. https://doi.org/10.14309/ajg.0000000000003208

11. St-Pierre, J., Klein, J., Choi, N. K., Fear, E., Pannain, S., & Rubin, D. T. (2024). Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease. Digestive diseases and sciences, 69(12), 4437–4445. https://doi.org/10.1007/s10620-024-08720-2

12. Alharbi S. H. (2024). Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Therapeutic advances in endocrinology and metabolism, 15, 20420188231222367. https://doi.org/10.1177/20420188231222367

13. Wang, W., Zhang, C., Zhang, H., Li, L., Fan, T., & Jin, Z. (2023). The alleviating effect and mechanism of GLP-1 on ulcerative colitis. Aging, 15(16), 8044–8060. https://doi.org/10.18632/aging.204953

14. Hunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021). GLP-1 and Intestinal Diseases. Biomedicines, 9(4), 383. https://doi.org/10.3390/biomedicines9040383

15. Saadoun, A. A., Abdelsattar, A. H., Elsaid, A. H., Abdelaleam, E. A., Abdelkader, H. K., Ibrahim, H. M., Saad, M. S., Ellawi, M. S., Elsaid, R. E., Maghrabia, A., Ibrahim, D., & Ramadan, N. M. (2025). Repurposing liraglutide to the management of DSS-induced colitis: a potential for promoting autophagy. Naunyn-Schmiedeberg's archives of pharmacology, 398(12), 17173–17185. https://doi.org/10.1007/s00210-025-04339-w

16. Klein, J. A., St-Pierre, J., Choi, D., Lopez, J., & Rubin, D. T. (2024). Dramatic Changes in Thiopurine Metabolite Levels in a Patient With Inflammatory Bowel Disease Treated With Tirzepatide for Weight Loss. ACG case reports journal, 11(11), e01544. https://doi.org/10.14309/crj.0000000000001544

17. Shneyderman, M., Freid, H., Kohler, D., Peraza, J., Haskey, N., Abbott, E., Kornbluth, A., Raman, M., & Gold, S. (2024). Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease. Gastroenterology & hepatology, 20(12), 712–722.

18. Villumsen, M., Schelde, A. B., Jimenez-Solem, E., Jess, T., & Allin, K. H. (2021). GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine, 37, 100979. https://doi.org/10.1016/j.eclinm.2021.100979

19. Alqinai, B., Adeniran, O., Adekolu, A., & Gayam, S. (2026). Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis. ACG case reports journal, 13(4), e02070. https://doi.org/10.14309/crj.0000000000002070

20. Drucker D. J. (2026). The expanding landscape of GLP-1 medicines. Nature medicine, 32(1), 47–57. https://doi.org/10.1038/s41591-025-04124-5

Quality in Sport

Downloads

  • PDF

Published

2026-10-02

How to Cite

1.
DRÓŻDŻ, Michał Antoni, MARCAK, Maria, NOWICKA, Weronika, KOŻUCH, Anna and RYMARCZYK, Emilia. Use of GLP-1 receptor agonists and dual agonists in patients with inflammatory bowel disease . Quality in Sport. Online. 2 October 2026. Vol. 77, p. 76265. [Accessed 18 November 2026]. DOI 10.12775/QS.2026.77.76265.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 77 (2026)

Section

Medical Sciences

License

Copyright (c) 2026 Michał Antoni Dróżdż, Maria Marcak, Weronika Nowicka, Anna Kożuch, Emilia Rymarczyk

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Stats

Number of views and downloads: 200
Number of citations: 0

Search

Search

Browse

  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

Inflammatory Bowel Disease, GLP-1 Receptor Agonists, Obesity, Tirzepatide, Mucosal Healing
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop